Business
NXP002 Pilot Study in Lung and Liver Fibrosis
NXP002 Pilot Study in Lung and Liver Fibrosis.
About this update from Nuformix Plc
[{"type":"text","content":"\n \nRNS Number : 4039D Nuformix PLC 31 January 2018 \n\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE UNITED STATES OF AMERICA OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.\n \n31 January 2018\nNuformix Plc\n(\"Nuformix\" or \"the Company\")\n \nPositive Results from NXP002 Pilot Study in Lung and Liver Fibrosis\n \nNuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces a positive outcome following innovative pilot studies in multiple fibrotic diseases for its NXP002 programme.\n \nSummary\n· Positive indication of efficacy using cutting-edge human tissue disease models\n· Demonstration that NXP002 inhibits fibrosis in functional human tissue via a dual-action, significantly addressing both inflammation and fibrosis components responsible for disease progression\n· Results show a profound effect in inhibiting established human fibrotic disease, offering future benefits to a wide spectrum of patients\n· Proven safety and tolerability offers significant advantages over competitor products \n· Rapidly growing markets already valued in multiple billions\n \nWorking in parallel with the University of Newcastle and Fibrofind and their proprietary fibrosis research models, Nuformix has completed pilot pre-clinical studies that further validate the potential for its NXP002 programme in successfully and safely treating fibrosis. \n \nFibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Using cutting-edge human tissue disease models, the studies have focussed on the potential for NXP002 to halt progression in established lung and liver fibrosis. The results demonstrate that NXP002 strongly inhibits fibrosis in functional human tissue via a dual-action, which significantly addresses both the inflammation and fibrosis components responsible for fibrotic disease progression. \n \nFollowing success in these innovative pilot studies Nuformix...